Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3CCH

H-2Db complex with murine gp100

Summary for 3CCH
Entry DOI10.2210/pdb3cch/pdb
Related3CH1
DescriptorH-2 class I histocompatibility antigen, D-B alpha chain, Beta-2-microglobulin, nonameric peptide murine gp100, ... (6 entities in total)
Functional Keywordsmurine mhc, glycoprotein, immune response, membrane, mhc i, transmembrane, disease mutation, melanin biosynthesis, immune system
Biological sourceMus musculus (mouse)
More
Cellular locationMembrane; Single-pass type I membrane protein: P01899
Secreted: P01887
Total number of polymer chains12
Total formula weight181974.50
Authors
Badia-Martinez, D.,Achour, A. (deposition date: 2008-02-25, release date: 2009-03-10, Last modification date: 2024-10-16)
Primary citationvan Stipdonk, M.J.,Badia-Martinez, D.,Sluijter, M.,Offringa, R.,van Hall, T.,Achour, A.
Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.
Cancer Res., 69:7784-7792, 2009
Cited by
PubMed Abstract: Immunogenicity of tumor-associated antigens (TAA) is often weak because many TAA are autoantigens for which the T-cell repertoire is sculpted by tolerance mechanisms. Substitutions at main anchor positions to increase the complementarity between the peptide and the MHC class I (MHC-I) binding cleft constitute a common procedure to improve binding capacity and immunogenicity of TAA. However, such alterations are tailored for each MHC-I allele and may recruit different CTL specificities through conformational changes in the targeted peptides. Comparative analysis of substituted melanoma-differentiation antigen gp100 in complex with H-2D(b) revealed that combined introduction of glycine and proline residues at the nonanchor positions 2 and 3, respectively, resulted in an agonistic altered peptide with dramatically enhanced binding affinity, stability, and immunogenicity of this TAA. Peptide vaccination using the p2Gp3P-altered peptide version of gp100 induced high frequencies of melanoma-specific CTL in the endogenous CD8+ repertoire. Crystal structure analysis of MHC/peptide complexes revealed that the conformation of the modified p2Gp3P-peptide was similar to the wild-type peptide, and indicated that this mimotope was stabilized through interactions between peptide residue p3P and the tyrosine residue Y159 that is conserved among most known MHC-I molecules throughout mammalian species. Our results may provide an alternative approach to enhance MHC stabilization capacity and immunogenicity of low-affinity peptides for induction of robust tumor-specific CTL.
PubMed: 19789338
DOI: 10.1158/0008-5472.CAN-09-1724
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon